|
1
|
Ryan PD and Goss PE: The emerging role of
the insulin-like growth factor pathway as a therapeutic target in
cancer. Oncologist. 13:16–24. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller BS and Yee D: Type I insulin-like
growth factor receptor as a therapeutic target in cancer. Cancer
Res. 65:10123–10127. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baserga R: Oncogenes and the strategy of
growth factors. Cell. 79:927–930. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adachi Y, Yamamoto H, Imsumran A, et al:
Insulin-like growth factor-I receptor as a candidate for a novel
molecular target in the gastrointestinal cancers. Dig Endosc.
18:245–251. 2006. View Article : Google Scholar
|
|
5
|
Furstenberger G and Senn HJ: Insulin-like
growth factors and cancer. Lancet Oncol. 3:298–302. 2002.
View Article : Google Scholar
|
|
6
|
Manning BD and Cantley LC: AKT/PKB
signaling: navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weber MM, Fottner C, Liu SB, Jung MC,
Engelhardt D and Baretton GB: Overexpression of the insulin-like
growth factor I receptor in human colon carcinomas. Cancer.
95:2086–2095. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang Y, Wang L, Gong W, Wei D, Le X, Yao
J, Ajani J, Abbruzzese JL, Huang S and Xie K: A high expression
level of insulin-like growth factor I receptor is associated with
increased expression of transcription factor Sp1 and regional lymph
node metastasis of human gastric cancer. Clin Exp Metastasis.
21:755–764. 2004. View Article : Google Scholar
|
|
10
|
Imsumran A, Adachi Y, Yamamoto H, et al:
Insulin-like growth factor-I receptor as a marker for prognosis and
a therapeutic target in human esophageal squamous cell carcinoma.
Carcinogenesis. 28:947–956. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bergmann U, Funatomi H, Yokoyama M, Beger
HG and Korc M: Insulin-like growth factor I overexpression in human
pancreatic cancer: evidence for autocrine and paracrine roles.
Cancer Res. 55:2007–2011. 1995.PubMed/NCBI
|
|
12
|
Zhang YC, Wang XP, Zhang LY, Song AL, Kou
ZM and Li XS: Effect of blocking IGF-I receptor on growth of human
hepatocellular carcinoma cells. World J Gastroenterol.
12:3977–3982. 2006.PubMed/NCBI
|
|
13
|
Samani AA, Yakar S, LeRoith D and Brodt P:
The role of the IGF system in cancer growth and metastasis:
overview and recent insights. Endocrine. 28:20–47. 2007.PubMed/NCBI
|
|
14
|
Chitnis MM, Yuen JS, Protheroe AS, Pollak
M and Macaulay VM: The type 1 insulin-like growth factor receptor
pathway. Clin Cancer Res. 14:6364–6370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kwon J, Stephan S, Mukhopadhyay A, Muders
MH, Dutta SK, Lau JS and Mukhopadhyay D: Insulin receptor
substrate-2- mediated insulin-like growth factor-I receptor
overexpression in pancreatic adenocarcinoma through protein kinase
Cdelta. Cancer Res. 69:1350–1357. 2009. View Article : Google Scholar
|
|
16
|
Almeida A, Muleris M, Dutrillaux B and
Malfoy B: The insulin-like growth factor I receptor gene is the
target for the 15q26 amplicon in breast cancer. Genes Chromosomes
Cancer. 11:63–65. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berns EM, Klijn JG, van Staveren IL,
Portengen H and Foekens JA: Sporadic amplification of the
insulin-like growth factor 1 receptor gene in human breast tumors.
Cancer Res. 52:1036–1039. 1992.PubMed/NCBI
|
|
18
|
Armengol G, Knuutila S, Lluís F, Capellà
G, Miró R and Caballín MR: DNA copy number changes and evaluation
of MYC, IGF1R and FES amplification in xenografts of pancreatic
adenocarcinoma. Cancer Genet Cytogenet. 116:133–141. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Natrajan R, Reis-Filho JS, Little SE,
Messahel B, Brundler MA, Dome JS, Grundy PE, Vujanic GM,
Pritchard-Jones K and Jones C: Blastemal expression of type I
insulin-like growth factor receptor in Wilms’ tumors is driven by
increased copy number and correlates with relapse. Cancer Res.
66:11148–11155. 2006.
|
|
20
|
Meng Z, Jackson NL, Choi H, King PH,
Emanuel PD and Blume SW: Alterations in RNA-binding activities of
IRES-regulatory proteins as a mechanism for physiological
variability and pathological dys-regulation of IGF-IR translational
control in human breast tumor cells. J Cell Physiol. 217:172–183.
2008. View Article : Google Scholar
|
|
21
|
Stattin P, Bylund A, Rinaldi S, Biessy C,
Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G and Kaaks R:
Plasma insulin-like growth factor-I, insulin-like growth
factor-binding proteins, and prostate cancer risk: a prospective
study. J Natl Cancer Inst. 92:1910–1917. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Palmqvist R, Hallmans G, Rinaldi S, Biessy
C, Stenling R, Riboli E and Kaaks R: Plasma insulin-like growth
factor 1, insulin-like growth factor binding protein 3 and risk of
colorectal cancer: a prospective study in northern Sweden. Gut.
50:642–646. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakamura M, Miyamoto S, Maeda H, Zhang SC,
Sangai T, Ishii G, Hasebe T, Endoh Y, Saito N, Asaka M and Ochiai
A: Low levels of insulin-like growth factor type 1 receptor
expression at cancer cell membrane predict liver metastasis in
Dukes’ C human colorectal cancers. Clin Cancer Res. 10:8434–8441.
2004.PubMed/NCBI
|
|
24
|
Höpfner M, Baradari V, Huether A, Schöfl C
and Scherübl H: The insulin-like growth factor receptor 1 is a
promising target for novel treatment approaches in neuroendocrine
gastrointestinal tumours. Endocr Relat Cancer. 13:135–149.
2006.PubMed/NCBI
|
|
25
|
Hopfner M, Sutter AP, Huether A, Baradari
V and Scherubl H: Tyrosine kinase of insulin-like growth factor
receptor as target for novel treatment and prevention strategies of
colorectal cancer. World J Gastroenterol. 12:5635–5643.
2006.PubMed/NCBI
|
|
26
|
Piao W, Wang Y, Adachi Y, et al:
Insulin-like growth factor-I receptor blockade by a specific
tyrosine kinase inhibitor for human gastrointestinal carcinomas.
Mol Cancer Ther. 7:1483–1493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bauer TW, Somcio RJ, Fan F, Liu W, Johnson
M, Lesslie DP, Evans DB, Gallick GE and Ellis LM: Regulatory role
of c-Met in insulin-like growth factor-I receptor-mediated
migration and invasion of human pancreatic carcinoma cells. Mol
Cancer Ther. 5:1676–1682. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reinmuth N, Fan F, Liu W, Parikh AA,
Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE and Ellis
LM: Impact of insulin-like growth factor receptor-I function on
angiogenesis, growth and metastasis of colon cancer. Lab Invest.
82:1377–1389. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gooch JL, van Den Berg CL and Yee D:
Insulin-like growth factor (IGF)-I rescues breast cancer cells from
chemotherapy-induced cell death-proliferative and anti-apoptotic
effects. Breast Cancer Res Treat. 56:1–10. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Perer ES, Madan AK, Shurin A, Zakris E,
Romeguera K, Pang Y and Beech DJ: Insulin-like growth factor I
receptor antagonism augments response to chemoradiation therapy in
colon cancer cells. J Surg Res. 94:1–5. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Min Y, Adachi Y, Yamamoto H, Imsumran A,
Arimura Y, Endo T, Hinoda Y, Lee CT, Nadaf S, Carbone DP and Imai
K: Insulin-like growth factor I receptor blockade enhances
chemotherapy and radiation responses and inhibits tumour growth in
human gastric cancer xenografts. Gut. 54:591–600. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ullrich A, Gray A, Tam AW, et al:
Insulin-like growth factor I receptor primary structure: comparison
with insulin receptor suggests structural determinants that define
functional specificity. EMBO J. 5:2503–2512. 1986.
|
|
33
|
Hofmann F and Garcia-Echeverria C:
Blocking the insulin-like growth factor-I receptor as a strategy
for targeting cancer. Drug Discov Today. 10:1041–1047. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee JS, Weiss J, Martin JL and Scott CD:
Increased expression of the mannose 6-phosphate/insulin-like growth
factor-II receptor in breast cancer cells alters tumorigenic
properties in vitro and in vivo. Int J Cancer. 107:564–570. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang X and Yee D: Insulin-like growth
factor binding protein-1 (IGFBP-1) inhibits breast cancer cell
motility. Cancer Res. 62:4369–4375. 2002.PubMed/NCBI
|
|
36
|
Goya M, Miyamoto S, Nagai K, et al: Growth
inhibition of human prostate cancer cells in human adult bone
implanted into nonobese diabetic/severe combined immunodeficient
mice by a ligand-specific antibody to human insulin-like growth
factors. Cancer Res. 64:6252–6258. 2004. View Article : Google Scholar
|
|
37
|
Pollak M: Insulin, insulin-like growth
factors and neoplasia. Best Pract Res Clin Endocrinol Metab.
22:625–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rodon J, DeSantos V, Ferry RJ Jr and
Kurzrock R: Early drug development of inhibitors of the
insulin-like growth factor-I receptor pathway: lessons from the
first clinical trials. Mol Cancer Ther. 7:2575–2588. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lacy MQ, Alsina M, Fonseca R, Paccagnella
ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M,
Jagannath S, Richardson P and Gualberto A: Phase I, pharmacokinetic
and pharmacodynamic study of the anti-insulin-like growth factor
type 1 receptor monoclonal antibody CP-751,871 in patients with
multiple myeloma. J Clin Oncol. 26:3196–3203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Karp DD, Paz-Ares LG, Novello S, Haluska
P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ,
Blumenschein G Jr, Johnson FM, Green S and Gualberto A: Phase II
study of the anti-insulin-like growth factor type 1 receptor
antibody CP-751,871 in combination with paclitaxel and carboplatin
in previously untreated, locally advanced, or metastatic non-small
cell lung cancer. J Clin Oncol. 27:2516–2522. 2009. View Article : Google Scholar
|
|
41
|
Cohen BD, Baker DA, Soderstrom C,
Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto
A, Beebe JS and Moyer JD: Combination therapy enhances the
inhibition of tumor growth with the fully human anti-type 1
insulin-like growth factor receptor monoclonal antibody CP-751,871.
Clin Cancer Res. 11:2063–2073. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Burtrum D, Zhu Z, Lu D, et al: A fully
human monoclonal antibody to the insulin-like growth factor I
receptor blocks ligand-dependent signaling and inhibits human tumor
growth in vivo. Cancer Res. 63:8912–8921. 2003.PubMed/NCBI
|
|
43
|
Allen GW, Saba C, Armstrong EA, Huang SM,
Benavente S, Ludwig DL, Hicklin DJ and Harari PM: Insulin-like
growth factor-I receptor signaling blockade combined with
radiation. Cancer Res. 67:1155–1162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu KD, Zhou L, Burtrum D, Ludwig DL and
Moore MA: Antibody targeting of the insulin-like growth factor I
receptor enhances the anti-tumor response of multiple myeloma to
chemotherapy through inhibition of tumor proliferation and
angiogenesis. Cancer Immunol Immunother. 56:343–357.
2007.PubMed/NCBI
|
|
45
|
Prewett M, Damoci C, Bassi R, Ludwig DL,
Hicklin DJ and Tonra JR: IMC-A12 enhances the efficacy of cetuximab
+ gemcitabine therapy in human pancreatic carcinoma xenografts.
Proc Am Assoc Cancer Res. 48:6522007.PubMed/NCBI
|
|
46
|
Tonra JR, Corcoran E, Makhoul G, et al:
Synergistic anti-tumor effects of anti-EGFR monoclonal antibody
Erbitux® combined with antibodies targeting IGF1R or
VEGFR-2. Proc Am Assoc Cancer Res. 46:11932005.
|
|
47
|
Goetsch L, Gonzalez A, Leger O, Beck A,
Pauwels PJ, Haeuw JF and Corvaia N: A recombinant humanized
anti-insulin-like growth factor receptor type I antibody (h7C10)
enhances the anti-tumor activity of vinorelbine and anti-epidermal
growth factor receptor therapy against human cancer xenografts. Int
J Cancer. 113:316–328. 2005. View Article : Google Scholar
|
|
48
|
Broussas M, Dupont J, Gonzalez A, Blaecke
A, Fournier M, Corvaïa N and Goetsch L: Molecular mechanisms
involved in activity of h7C10, a humanized monoclonal antibody, to
IGF-1 receptor. Int J Cancer. 124:2281–2293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pandini G, Wurch T, Akla B, et al:
Functional responses and in vivo anti-tumour activity of h7C10: a
humanised monoclonal antibody with neutralising activity against
the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1
hybrid receptors. Eur J Cancer. 43:1318–1327. 2007. View Article : Google Scholar
|
|
50
|
Youngren JF, Gable K, Penaranda C, Maddux
BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J and Goldfine ID:
Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and
c-erbB2/HER2/neu receptors and suppresses growth in breast cancer
cells. Breast Cancer Res Treat. 94:37–46. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zavodovskaya M, Campbell MJ, Maddux BA,
Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF and
Goldfine ID: Nordihydroguaiaretic acid (NDGA), an inhibitor of the
HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of
HER2-overexpressing human breast cancer cells. J Cell Biochem.
103:624–635. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rowe DL, Ozbay T, Bender LM and Nahta R:
Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I
receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol
Cancer Ther. 7:1900–1908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ryan CJ, Harzstark AH, Rosenberg J, Lin A,
Claros C, Goldfine ID, Kerner JF, Small EJ and Youngren JF: A pilot
dose-escalation study of the effects of nordihydroguareacetic acid
on hormone and prostate specific antigen levels in patients with
relapsed prostate cancer. BJU Int. 101:436–439. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Garcia-Echeverria C, Pearson MA, Marti A,
et al: In vivo antitumor activity of NVP-AEW541 – a novel, potent
and selective inhibitor of the IGF-IR kinase. Cancer Cell.
53:231–239. 2004.
|
|
55
|
Moser C, Schachtschneider P, Lang SA,
Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK and
Stoeltzing O: Inhibition of insulin-like growth factor-I receptor
(IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor,
reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J
Cancer. 44:1577–1586. 2008. View Article : Google Scholar
|
|
56
|
Höpfner M, Huether A, Sutter AP, Baradari
V, Schuppan D and Scherübl H: Blockade of IGF-1 receptor tyrosine
kinase has antineoplastic effects in hepatocellular carcinoma
cells. Bio Chem Pharmacol. 71:1435–1448. 2006.
|
|
57
|
Kaulfuss S, Burfeind P, Gaedcke J and
Scharf JG: Dual silencing of insulin-like growth factor-I receptor
and epidermal growth factor receptor in colorectal cancer cells is
associated with decreased proliferation and enhanced apoptosis. Mol
Cancer Ther. 8:821–833. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Favelyukis S, Till JH, Hubbard SR and
Miller WT: Structure and autoregulation of the insulin-like growth
factor 1 receptor kinase. Nat Struct Biol. 8:1058–1063. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Girnita A, Girnita L, del Prete F,
Bartolazzi A, Larsson O and Axelson M: Cyclolignans as inhibitors
of the insulin-like growth factor-1 receptor and malignant cell
growth. Cancer Res. 64:236–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Vasilcanu D, Girnita A, Girnita L,
Vasilcanu R, Axelson M and Larsson O: The cyclolignan PPP induces
activation loop-specific inhibition of tyrosine phosphorylation of
the insulin-like growth factor-1 receptor. Link to the phosphatidyl
inositol-3 kinase/Akt apoptotic pathway. Oncogene. 23:7854–7862.
2004. View Article : Google Scholar
|
|
61
|
Menu E, Jernberg-Wiklund H, Stromberg T,
de Raeve H, Girnita L, Larsson O, Axelson M, Asosingh K, Nilsson K,
van Camp B and Vanderkerken K: Inhibiting the IGF-1 receptor
tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo
study in the 5T33MM mouse model. Blood. 107:655–660. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Nussbaum T, Samarin J, Ehemann V,
Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher
P and Breuhahn K: Autocrine insulin-like growth factor-II
stimulation of tumor cell migration is a progression step in human
hepatocarcinogenesis. Hepatology. 48:146–156. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Menu E, Jernberg-Wiklund H, de Raeve H, et
al: Targeting the IGF-1R using picropodophyllin in the
therapeutical 5T2MM mouse model of multiple myeloma: beneficial
effects on tumor growth, angiogenesis, bone disease and survival.
Int J Cancer. 121:1857–1861. 2007. View Article : Google Scholar
|
|
64
|
Vasilcanu R, Vasilcanu D, Rosengren L,
Natalishvili N, Sehat B, Yin S, Girnita A, Axelson M, Girnita L and
Larsson O: Picropodophyllin induces downregulation of the
insulin-like growth factor 1 receptor: potential mechanistic
involvement of Mdm2 and beta-arrestin1. Oncogene. 27:1629–1638.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Vasilcanu R, Vasilcanu D, Sehat B, Yin S,
Girnita A, Axelson M and Girnita L: Insulin-like growth factor
type-I receptor-dependent phosphorylation of extracellular
signal-regulated kinase 1/2 but not Akt (protein kinase B) can be
induced by picropodophyllin. Mol Pharmacol. 73:930–939. 2008.
View Article : Google Scholar
|
|
66
|
Linder S, Shoshan MC and Gupta RS:
Picropodophyllotoxin or podophyllotoxin does not induce cell death
via insulin-like growth factor-I receptor. Cancer Res.
67:2899–2900. 2007. View Article : Google Scholar : PubMed/NCBI
|
